2023 Fiscal Year Final Research Report
Development of an ultra-sensitive electrochemiluminescence immunoassay using multiple particle binding-ionic liquid nanoparticles
| Project/Area Number |
21K06523
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 47020:Pharmaceutical analytical chemistry and physicochemistry-related
|
|---|
| Research Institution | Kyoto Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | イオン液体 / ナノ粒子 / 電気化学発光 / イムノアッセイ / リポソーム |
|---|
| Outline of Final Research Achievements |
In order to establish an ultrasensitive electrochemiluminescence immunoassay (ECLIA) method, the ILNP-ECLIA using ionic liquid nanoparticles (ILNP) was developed. The calibration curve for a model analyte, avidin (AVI), had a good linearity over the AVI concentration range of 1 to 10 μM. Although the ILNP-ECLIA is slightly low in the sensitivity, it has the advantage of being able to observe ECL in their particle state, and therefore it has been demonstrated that it may be possible to perform immunoassays easily.
|
| Free Research Field |
分析化学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究課題で開発したイオン液体ナノ粒子（ILNP）を用いた電気化学発光イムノアッセイ（ILNP-ECLIA）法は、粒子状態で電気化学発光（ECL）を観測できるという点が、本研究成果の学術的意義である。また、ILNP-ECLIA法は原理的には一般的なイムノアッセイ系を用いているため、分析可能なバイオマーカーの適用範囲が広い。したがって、種々の難治性疾患に関与するバイオマーカーを測定できるため、難治性疾患の超早期診断につなげることができるという点が本研究成果の社会的意義である。
|
